Skip to main content

INMUNOTERAPIA CELULAR ADOPTIVA CON CAR CD5 "SINGULAR O DUAL" PARA TRATAMIENTO DE LLA-T PEDIATRICA E INFECCIONES FUNGICAS POST-TRANSPLANTE ALOGENICO DE PROGENITORES HEMATOPOIETICOS

PI17/01028

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2017
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO DE INVESTIGACION CONTRA LA LEUCEMIA JOSEP CARRERAS
Execution centre FUNDACION INSTITUTO DE INVESTIGACION CONTRA LA LEUCEMIA JOSEP CARRERAS

Resultados relacionados

Resultados totales (Incluyendo duplicados): 12
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Robustness of Catalytically Dead Cas9 Activators in Human Pluripotent and Mesenchymal Stem Cells

  • Petazzi, Paolo|||0000-0002-1036-2895
  • Torres, Raul|||0000-0001-9606-0398
  • Fidanza, Andrea|||0000-0001-7766-0806
  • Roca Ho, Heleia|||0000-0001-7324-5234
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Castaño Cardoso, Julio|||0000-0002-0712-5856
  • Rodriguez-Perales, Sandra|||0000-0001-7221-3636
  • Díaz de la Guardia, Rafael|||0000-0001-9568-6719
  • López-Millán, Belén|||0000-0002-9757-5454
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Forrester, L. M.
  • Bueno, Clara|||0000-0003-1442-6216
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Human pluripotent stem cells (hPSCs) and mesenchymal stromal/stem cells (hMSCs) are clinically relevant sources for cellular therapies and for modeling human development and disease. Many stem cell-based applications rely on the ability to activate several endogenous genes simultaneously to modify cell fate. However, genetic intervention of these cells remains challenging. Several catalytically dead Cas9 (dCas9) proteins fused to distinct activation domains can modulate gene expression when directed to their regulatory regions by a specific single-guide RNA (sgRNA). In this study, we have compared the ability of the first-generation dCas9-VP64 activator and the second-generation systems, dCas9-SAM and dCas9-SunTag, to induce gene expression in hPSCs and hMSCs. Several stem cell lines were tested for single and multiplexed gene activation. When the activation of several genes was compared, all three systems induced specific and potent gene expression in both single and multiplexed settings, but the dCas9-SAM and dCas9-SunTag systems resulted in the highest and most consistent level of gene expression. Simultaneous targeting of the same gene with multiple sgRNAs did not result in additive levels of gene expression in hPSCs nor hMSCs. We demonstrate the robustness and specificity of second-generation dCas9 activators as tools to simultaneously activate several endogenous genes in clinically relevant human stem cells.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo

  • Libero Baroni, Matteo
  • Sánchez Martínez, Diego|||0000-0003-4605-5325
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Roca Ho, Heleia|||0000-0001-7324-5234
  • Castellà, Maria
  • Zanetti, S. R.|||0000-0002-9052-8751
  • Velasco-Hernández, Talia|||0000-0003-2183-7443
  • Díaz de la Guardia, Rafael|||0000-0001-9568-6719
  • Castaño Cardoso, Julio|||0000-0002-0712-5856
  • Anguita, Eduardo|||0000-0003-1386-4943
  • Vives Polo, Susana|||0000-0003-2217-5285
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Lapillone, Helene
  • Bras, Anne E.
  • Van Der Velden, Vincent H. J.
  • Junca, Jordi|||0000-0003-0142-772X
  • Marin, Pedro
  • Bataller, Alex|||0000-0002-6085-2745
  • Esteve Reyner, Jordi|||0000-0002-8056-648X
  • Vick, Binje
  • Jeremias, Irmela|||0000-0003-1773-7677
  • Lopez, Angel
  • Sorigue, Marc|||0000-0002-0587-591X
  • Bueno, Clara|||0000-0003-1442-6216
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
BACKGROUND: Acute myeloid leukemia (AML) is a hematopoietic malignancy which is biologically, phenotypically and genetically very heterogeneous. Outcome of patients with AML remains dismal, highlighting the need for improved, less toxic therapies. Chimeric antigen receptor T-cell (CART) immunotherapies for patients with refractory or relapse (R/R) AML are challenging because of the absence of a universal pan-AML target antigen and the shared expression of target antigens with normal hematopoietic stem/progenitor cells (HSPCs), which may lead to life-threating on-target/off-tumor cytotoxicity. CD33-redirected and CD123-redirected CARTs for AML are in advanced preclinical and clinical development, and they exhibit robust antileukemic activity. However, preclinical and clinical controversy exists on whether such CARTs are myeloablative. METHODS: We set out to comparatively characterize in vitro and in vivo the efficacy and safety of 41BB-based and CD28-based CARCD123. We analyzed 97 diagnostic and relapse AML primary samples to investigate whether CD123 is a suitable immunotherapeutic target, and we used several xenograft models and in vitro assays to assess the myeloablative potential of our second-generation CD123 CARTs. RESULTS: Here, we show that CD123 represents a bona fide target for AML and show that both 41BB-based and CD28-based CD123 CARTs are very efficient in eliminating both AML cell lines and primary cells in vitro and in vivo. However, both 41BB-based and CD28-based CD123 CARTs ablate normal human hematopoiesis and prevent the establishment of de novo hematopoietic reconstitution by targeting both immature and myeloid HSPCs. CONCLUSIONS: This study calls for caution when clinically implementing CD123 CARTs, encouraging its preferential use as a bridge to allo-HSCT in patients with R/R AML.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells

  • Martinez-Lage , Marta|||0000-0001-5535-025X
  • Torres, Raul|||0000-0001-9606-0398
  • Puig-Serra, Pilar|||0000-0002-7802-4972
  • Moreno-Gaona, Patricia
  • Martin, M. Carmen
  • Moya, Francisco J.
  • Quintana-Bustamante, Oscar|||0000-0002-6869-7006
  • Garcia-Silva, Susana|||0000-0003-1065-0245
  • Carcaboso, Angel M.|||0000-0002-8485-426X
  • Petazzi, Paolo|||0000-0002-1036-2895
  • Bueno, Clara|||0000-0003-1442-6216
  • Català-Mora, Jaume|||0000-0003-2152-8579
  • Peinado, Héctor|||0000-0002-4256-3413
  • Segovia, Jose C.|||0000-0003-4101-6124
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Rodriguez-Perales, Sandra|||0000-0001-7221-3636
Fusion oncogenes (FOs) are common in many cancer types and are powerful drivers of tumor development. Because their expression is exclusive to cancer cells and their elimination induces cell apoptosis in FO-driven cancers, FOs are attractive therapeutic targets. However, specifically targeting the resulting chimeric products is challenging. Based on CRISPR/Cas9 technology, here we devise a simple, efficient and non-patient-specific gene-editing strategy through targeting of two introns of the genes involved in the rearrangement, allowing for robust disruption of the FO specifically in cancer cells. As a proof-of-concept of its potential, we demonstrate the efficacy of intron-based targeting of transcription factors or tyrosine kinase FOs in reducing tumor burden/mortality in in vivo models. The FO targeting approach presented here might open new horizons for the selective elimination of cancer cells.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Efficient elimination of primary B-ALL cells in vitro and in vivo using a novel 4-1BB-based CAR targeting a membrane-distal CD22 epitope

  • Velasco-Hernández, Talia|||0000-0003-2183-7443
  • Zanetti, S. R.|||0000-0002-9052-8751
  • Roca Ho, Heleia|||0000-0001-7324-5234
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Petazzi, Paolo|||0000-0002-1036-2895
  • Sánchez Martínez, Diego|||0000-0003-4605-5325
  • Molina, Oscar|||0000-0001-7585-4519
  • Baroni, Matteo Libero|||0000-0001-8265-2050
  • Fuster, José Luis|||0000-0002-4881-9440
  • Ballerini, Paola
  • Bueno, Clara|||0000-0003-1442-6216
  • Fernández-Fuentes, Narcís
  • Engel, Pablo|||0000-0001-8410-252X
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Background There are few therapeutic options available for patients with B-cell acute lymphoblastic leukemia (B-ALL) relapsing as CD19 - either after chemotherapy or CD19-targeted immunotherapies. CD22-chimeric antigen receptor (CAR) T cells represent an attractive addition to CD19-CAR T cell therapy because they will target both CD22 + CD19 - B-ALL relapses and CD19 - preleukemic cells. However, the immune escape mechanisms from CD22-CAR T cells, and the potential contribution of the epitope binding of the anti-CD22 single-chain variable fragment (scFv) remain understudied. Methods Here, we have developed and comprehensively characterized a novel CD22-CAR (clone hCD22.7) targeting a membrane-distal CD22 epitope and tested its cytotoxic effects against B-ALL cells both in in vitro and in vivo assays. Results Conformational epitope mapping, cross-blocking, and molecular docking assays revealed that the hCD22.7 scFv is a high-affinity binding antibody which specifically binds to the ESTKDGKVP sequence, located in the Ig-like V-type domain, the most distal domain of CD22. We observed efficient killing of B-ALL cells in vitro, although the kinetics were dependent on the level of CD22 expression. Importantly, we show an efficient in vivo control of patients with B-ALL derived xenografts with diverse aggressiveness, coupled to long-term hCD22.7-CAR T cell persistence. Remaining leukemic cells at sacrifice maintained full expression of CD22, ruling out CAR pressure-mediated antigen loss. Finally, the immunogenicity capacity of this hCD22.7-scFv was very similar to that of other CD22 scFv previously used in adoptive T cell therapy. Conclusions We report a novel, high-affinity hCD22.7 scFv which targets a membrane-distal epitope of CD22. 4-1BB-based hCD22.7-CAR T cells efficiently eliminate clinically relevant B- CD22 high and CD22 low ALL primary samples in vitro and in vivo. Our study supports the clinical translation of this hCD22.7-CAR as either single or tandem CD22-CD19-CAR for both naive and anti-CD19-resistant patients with B-ALL.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Enhanced hemato-endothelial specification during human embryonic differentiation through developmental cooperation between AF4-MLL and MLL-AF4 fusions

  • Bueno, Clara|||0000-0003-1442-6216
  • Calero-Nieto, Fernando|||0000-0003-3358-8253
  • Wang, X.
  • Valdés-Mas, Rafael
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Roca Ho, Heleia|||0000-0001-7324-5234
  • Ayllon, Veronica
  • Real, P. J.
  • Arambilet Mobilla, David|||0000-0001-7372-0082
  • Espinosa, Lluis|||0000-0002-2897-4099
  • Torres, Raul|||0000-0001-9606-0398
  • Agraz-Doblás, Antonio|||0000-0003-1307-4175
  • Varela, Ignacio|||0000-0002-0969-506X
  • De Boer, J.
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Gottgens, B.
  • Marschalek, Rolf|||0000-0003-4870-3445
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
The t(4;11)(q21;q23) translocation is associated with high-risk infant pro-B-cell acute lymphoblastic leukemia and arises prenatally during embryonic/fetal hematopoiesis. The developmental/pathogenic contribution of the t(4;11)-resulting MLL-AF4 (MA4) and AF4-MLL (A4M) fusions remains unclear; MA4 is always expressed in patients with t(4;11)+ B-cell acute lymphoblastic leukemia, but the reciprocal fusion A4M is expressed in only half of the patients. Because prenatal leukemogenesis manifests as impaired early hematopoietic differentiation, we took advantage of well-established human embryonic stem cell-based hematopoietic differentiation models to study whether the A4M fusion cooperates with MA4 during early human hematopoietic development. Co-expression of A4M and MA4 strongly promoted the emergence of hemato-endothelial precursors, both endothelial- and hemogenic-primed. Double fusionexpressing hemato-endothelial precursors specified into significantly higher numbers of both hematopoietic and endothelial-committed cells, irrespective of the differentiation protocol used and without hijacking survival/proliferation. Functional analysis of differentially expressed genes and differentially enriched H3K79me3 genomic regions by RNA-sequencing and H3K79me3 chromatin immunoprecipitation-sequencing, respectively, confirmed a hematopoietic/endothelial cell differentiation signature in double fusion-expressing hemato-endothelial precursors. Importantly, chromatin immunoprecipitation-sequencing analysis revealed a significant enrichment of H3K79 methylated regions specifically associated with HOX-A cluster genes in double fusion-expressing differentiating hematopoietic cells. Overall, these results establish a functional and molecular cooperation between MA4 and A4M fusions during human hematopoietic development.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia

  • López-Millán, Belén|||0000-0002-9757-5454
  • Sánchez Martínez, Diego|||0000-0003-4605-5325
  • Roca Ho, Heleia|||0000-0001-7324-5234
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Molina, Oscar|||0000-0001-7585-4519
  • Díaz de la Guardia, Rafael|||0000-0001-9568-6719
  • Torres, Raul|||0000-0001-9606-0398
  • Fuster, José Luis|||0000-0002-4881-9440
  • Ballerini, Paola
  • Suessbier, U.
  • Nombela-Arrieta, Cesar|||0000-0003-0415-259X
  • Bueno, Clara|||0000-0003-1442-6216
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
B cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer, with cure rates of ∼80%. MLL-rearranged (MLLr) B-ALL (MLLr-B-ALL) has, however, an unfavorable prognosis with common therapy refractoriness and early relapse, and therefore new therapeutic targets are needed for relapsed/refractory MLLr-B-ALL. MLLr leukemias are characterized by the specific expression of chondroitin sulfate proteoglycan-4, also known as neuron-glial antigen-2 (NG2). NG2 was recently shown involved in leukemia invasiveness and central nervous system infiltration in MLLr-B-ALL, and correlated with lower event-free survival (EFS). We here hypothesized that blocking NG2 may synergize with established induction therapy for B-ALL based on vincristine, glucocorticoids, and l-asparaginase (VxL). Using robust patient-derived xenograft (PDX) models, we found that NG2 is crucial for MLLr-B-ALL engraftment upon intravenous (i.v.) transplantation. In vivo blockade of NG2 using either chondroitinase-ABC or an anti-NG2-specific monoclonal antibody (MoAb) resulted in a significant mobilization of MLLr-B-ALL blasts from bone marrow (BM) to peripheral blood (PB) as demonstrated by cytometric and 3D confocal imaging analysis. When combined with either NG2 antagonist, VxL treatment achieved higher rates of complete remission, and consequently higher EFS and delayed time to relapse. Mechanistically, anti-NG2 MoAb induces neither antibody-dependent cell-mediated not complement-dependent cytotoxicity. NG2 blockade rather overrides BM stroma-mediated chemoprotection through PB mobilization of MLLr-B-ALL blasts, thus becoming more accessible to chemotherapy. We provide a proof of concept for NG2 as a therapeutic target for MLLr-B-ALL.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Engraftment characterization of risk-stratified AML in NSGS mice

  • Díaz de la Guardia, Rafael|||0000-0001-9568-6719
  • Velasco-Hernández, Talia|||0000-0003-2183-7443
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Roca Ho, Heleia|||0000-0001-7324-5234
  • Molina, Oscar|||0000-0001-7585-4519
  • Nombela-Arrieta, Cesar|||0000-0003-0415-259X
  • Bataller, Alex|||0000-0002-6085-2745
  • Fuster, José Luis|||0000-0002-4881-9440
  • Anguita, Eduardo|||0000-0003-1386-4943
  • Vives Polo, Susana|||0000-0003-2217-5285
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Gomez Casares, Maria Teresa|||0000-0003-0505-5126
  • Ramírez, Manuel|||0000-0003-0332-6973
  • Lapillonne, Hélène|||0000-0002-6900-8313
  • Ramos-Mejía, Verónica|||0000-0002-8013-4273
  • Rodríguez-Manzaneque, Juan Carlos|||0000-0001-5951-7029
  • Bueno, Clara|||0000-0003-1442-6216
  • López-Millán, Belén|||0000-0002-9757-5454
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Disease heterogeneity is well documented, and patient stratification determines treatment decisions. Patient-derived xenografts (PDXs) from risk-stratified AML are crucial for studying AML biology and testing novel therapeutics. Despite recent advances in PDX modeling of AML, reproducible engraftment of human AML is primarily limited to high-risk (HR) cases, with inconsistent or very protracted engraftment observed for favorable-risk (FR) and intermediate-risk (IR) patients. We used NSGS mice to characterize the engraftment robustness/kinetics of 28 AML patient samples grouped according to molecular/ cytogenetic classification and assessed whether the orthotopic coadministration of patientmatched bone marrow mesenchymal stromal cells (BM MSCs) improves AML engraftment. PDX event-free survival correlated well with the predictable prognosis of risk-stratified AML patients. The majority (85-94%) of the mice were engrafted in bone marrow (BM) independently of the risk group, although HR AML patients showed engraftment levels that were significantly superior to those of FR or IR AML patients. Importantly, the engraftment levels observed in NSGS mice by week 6 remained stable over time. Serial transplantation and long-term culture-initiating cell (LTC-IC) assays revealed long-term engraftment limited to HR AML patients, fitter leukemia-initiating cells (LICs) in HR AML samples, and the presence of AML LICs in the CD342 leukemic fraction, regardless of the risk group. Finally, orthotopic coadministration of patient-matched BM MSCs and AML cells was dispensable for BM engraftment levels but favored peripheralization of engrafted AML cells. This comprehensive characterization of human AML engraftment in NSGS mice offers a valuable platform for in vivo testing of targeted therapies in risk-stratified AML patient samples.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia

  • Ramos-Muntada, Mireia|||0000-0002-5531-1442
  • Trincado Alonso, Juan Luis, 1987-|||0000-0001-5363-3774
  • Blanco, Joan|||0000-0003-0647-3856
  • Bueno, Clara|||0000-0003-1442-6216
  • Rodríguez-Cortez, Virginia Carolina|||0000-0002-0853-247X
  • Bataller, Alex|||0000-0002-6085-2745
  • López-Millán, Belén|||0000-0002-9757-5454
  • Schwab, Claire
  • Ortega, Margarita
  • Velasco Puyo, Pablo|||0000-0001-7331-9483
  • Blanco, María L.
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Ramírez, Manuel|||0000-0003-0332-6973
  • Minguela, Alfredo|||0000-0003-2472-5893
  • Fuster, José Luis|||0000-0002-4881-9440
  • Cuatrecasas, Esther|||0000-0003-2881-4412
  • Camós, Mireia|||0000-0003-3658-7942
  • Ballerini, Paola
  • Escherich, Gabriele
  • Boer, Judith
  • DenBoer, Monique
  • Hernández Rivas, Jesús María|||0000-0002-9661-9371
  • Calasanz, M.J.|||0000-0002-0374-3008
  • Cazzaniga, Giovanni|||0000-0003-2955-4528
  • Harrison, Christine J.
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Molina, Oscar|||0000-0001-7585-4519
B-cell acute lymphoblastic leukemia (B-ALL) is the commonest childhood cancer. High hyperdiploidy (HHD) identifies the most frequent cytogenetic subgroup in childhood B-ALL. Although hyperdiploidy represents an important prognostic factor in childhood B-ALL, the specific chromosome gains with prognostic value in HHD-B-ALL remain controversial, and the current knowledge about the hierarchy of chromosome gains, clonal heterogeneity and chromosomal instability in HHD-B-ALL remains very limited. We applied automated sequential-iFISH coupled with single-cell computational modeling to identify the specific chromosomal gains of the eight typically gained chromosomes in a large cohort of 72 primary diagnostic (DX, n = 62) and matched relapse (REL, n = 10) samples from HHD-B-ALL patients with either favorable or unfavorable clinical outcome in order to characterize the clonal heterogeneity, specific chromosome gains and clonal evolution. Our data show a high degree of clonal heterogeneity and a hierarchical order of chromosome gains in DX samples of HHD-B-ALL. The rates of specific chromosome gains and clonal heterogeneity found in DX samples differ between HHD-B-ALL patients with favorable or unfavorable clinical outcome. In fact, our comprehensive analyses at DX using a computationally defined risk predictor revealed low levels of trisomies +18+10 and low levels of clonal heterogeneity as robust relapse risk factors in minimal residual disease (MRD)-negative childhood HHD-B-ALL patients: relapse-free survival beyond 5 years: 22.1% versus 87.9%, P < 0.0001 and 33.3% versus 80%, P < 0.0001, respectively. Moreover, longitudinal analysis of matched DX-REL HHD-B-ALL samples revealed distinct patterns of clonal evolution at relapse. Our study offers a reliable prognostic sub-stratification of pediatric MRD-negative HHD-B-ALL patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The insecticides permethrin and chlorpyrifos show limited genotoxicity and no leukemogenic potential in human and murine hematopoietic stem progenitor cells

  • Rodriguez-Cortez, Virginia C.
  • Navarrete-Meneses, Maria Pilar
  • Molina, Oscar|||0000-0001-7585-4519
  • Velasco-Hernández, Talia|||0000-0003-2183-7443
  • González, Jéssica
  • Romecín, Paola Alejandra|||0000-0001-6890-5883
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Roca Ho, Heleia|||0000-0001-7324-5234
  • Vinyoles, Meritxell|||0000-0003-1906-4701
  • Kowarz, Eric
  • Marin, Pedro
  • Rodriguez-Perales, Sandra|||0000-0001-7221-3636
  • Gomez-Marin, Carlos
  • Perez-Vera, Patricia
  • Cortes-Ledesma, Felipe
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Terron, Andrea
  • Bueno, Clara|||0000-0003-1442-6216
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

CD34 + CD19 - CD22 + B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies

  • Bueno, Clara|||0000-0003-1442-6216
  • Barrera, Susana
  • Bataller, Alex|||0000-0002-6085-2745
  • Ortiz-Maldonado, Valentín|||0000-0003-4699-6862
  • Elliot, Natalina
  • O'Byrne, Sorcha|||0000-0002-3116-1646
  • Wang, Guanlin
  • Rovira, Montse
  • Gutiérrez-Agüera, Francisco|||0000-0002-8620-2839
  • Trincado Alonso, Juan Luis, 1987-|||0000-0001-5363-3774
  • González-González, María|||0000-0001-8115-1086
  • Morgades, Mireia|||0000-0003-0295-2534
  • Sorigue, Marc|||0000-0002-0587-591X
  • Bárcena, Paloma
  • Zanetti, S. R.|||0000-0002-9052-8751
  • Torrebadell, Montse|||0000-0002-0027-3215
  • Vega-Garcia, Nerea
  • Rives, Susana|||0000-0002-5658-1831
  • Mallo, Maria del Mar|||0000-0001-7741-498X
  • Sole, F.|||0000-0002-3251-2161
  • Mead, Adam J.|||0000-0001-8522-1002
  • Roberts, Irene|||0000-0002-6094-6397
  • Thongjuea, Supat|||0000-0002-9129-4694
  • Psaila, Bethan|||0000-0001-8198-9663
  • Juan, Manel|||0000-0002-3064-1648
  • Delgado, Julio|||0000-0002-5157-4376
  • Urbano Ispizua, Álvaro|||0000-0002-7529-9399
  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Orfao, Alberto|||0000-0002-0007-7230
  • Roy, Anindita
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Three article in this issue present preclinical data aimed at improving immunotherapeutic approaches for relapsed B- and T-cell acute lymphoblastic leukemia (T-ALL). Chimeric antigen receptor T (CAR-T) cell therapy directed against relapsed T-ALL is hampered by difficulty in identifying a target antigen that is not also expressed on healthy T cells, risking "fratricide" with T-cell aplasia and loss of the CAR-T cells. Maciocia and colleagues identify CCR9 as an antigen expressed on.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Development of a Novel Anti-CD19 Chimeric Antigen Receptor, A Paradigm for an Affordable CAR T Cell Production at Academic Institutions

  • Castellà, Maria
  • Boronat, Anna|||0000-0003-0852-3634
  • Martín-Ibáñez, Raquel
  • Rodríguez, Vanina
  • Suñé, Guillermo|||0000-0002-4034-4348
  • Caballero Baños, Miguel|||0000-0002-2313-7988
  • Marzal, Berta
  • Pérez-Amill, Lorena|||0000-0003-0674-4660
  • Martín-Antonio, B.|||0000-0003-0612-2693
  • Castaño Cardoso, Julio|||0000-0002-0712-5856
  • Bueno, Clara|||0000-0003-1442-6216
  • Balagué, Olga|||0000-0002-5099-3675
  • González-Navarro, Europa Azucena|||0000-0003-3310-5557
  • Serra-Pages, Carles
  • Engel, Pablo|||0000-0001-8410-252X
  • Vilella, Ramon
  • Benítez Ribas, Daniel|||0000-0002-2346-5324
  • Ortiz-Maldonado, Valentín|||0000-0003-4699-6862
  • Cid, Joan|||0000-0001-5445-4508
  • Tabera, Jaime|||0000-0002-5430-0151
  • Canals, Josep M.|||0000-0001-6829-7670
  • Lozano, Miquel|||0000-0003-2593-833X
  • Baumann, Tycho|||0000-0003-4421-0088
  • Vilarrodona, Ana|||0000-0001-6984-1834
  • Trias, Esteve|||0000-0001-7635-4428
  • Campo, Elias|||0000-0001-9850-9793
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Urbano Ispizua, Álvaro|||0000-0002-7529-9399
  • Yagüe, Jordi|||0000-0001-8210-1929
  • Pérez-Galán, Patricia|||0000-0003-3895-5024
  • Rives, Susana|||0000-0002-5658-1831
  • Delgado, Julio|||0000-0002-5157-4376
  • Juan, Manel|||0000-0002-3064-1648
Genetically modifying autologous T cells to express an anti-CD19 chimeric antigen receptor (CAR) has shown impressive response rates for the treatment of CD19+ B cell malignancies in several clinical trials (CTs). Making this treatment available to our patients prompted us to develop a novel CART19 based on our own anti-CD19 antibody (A3B1), followed by CD8 hinge and transmembrane region, 4-1BB- and CD3z-signaling domains. We show that A3B1 CAR T cells are highly cytotoxic and specific against CD19+ cells in vitro, inducing secretion of pro-inflammatory cytokines and CAR T cell proliferation. In vivo, A3B1 CAR T cells are able to fully control disease progression in an NOD.Cg-Prkdc Il2rd/SzJ (NSG) xenograph B-ALL mouse model. Based on the pre-clinical data, we conclude that our CART19 is clearly functional against CD19+ cells, to a level similar to other CAR19s currently being used in the clinic. Concurrently, we describe the implementation of our CAR T cell production system, using lentiviral vector and CliniMACS Prodigy, within a medium-sized academic institution. The results of the validation phase show our system is robust and reproducible, while maintaining a low cost that is affordable for academic institutions. Our model can serve as a paradigm for similar institutions, and it may help to make CAR T cell treatment available to all patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Chromosomal instability in aneuploid acute lymphoblastic leukemia associates with disease progression

  • Molina, Oscar|||0000-0001-7585-4519
  • Ortega-Sabater, C.
  • Thampi, Namitha|||0000-0001-6166-583X
  • Fernández Fuentes, Narcís|||0000-0002-6421-1080
  • Guerrero Murillo, Mercedes|||0000-0002-5556-2460
  • Martínez Moreno, Alba|||0000-0001-7514-260X
  • Vinyoles, Meritxell|||0000-0003-1906-4701
  • Velasco-Hernández, Talia|||0000-0003-2183-7443
  • Bueno, Clara|||0000-0003-1442-6216
  • Trincado Alonso, Juan Luis, 1987-|||0000-0001-5363-3774
  • Granada, Isabel|||0000-0002-4275-0104
  • Campos, Diana
  • Giménez, Carles
  • Boer, Judith M.|||0000-0003-4848-7789
  • den Boer, Monique L.
  • Calvo, Gabriel F.|||0000-0002-3623-236X
  • Camós, Mireia|||0000-0003-3658-7942
  • Fuster, José Luis|||0000-0002-4881-9440
  • Velasco Puyo, Pablo|||0000-0001-7331-9483
  • Ballerini, Paola
  • Locatelli, Franco|||0000-0002-7976-3654
  • Mullighan, Charles G.|||0000-0002-1871-1850
  • Spierings, Diana C.J.|||0000-0001-8403-474X
  • Foijer, Floris|||0000-0003-0989-3127
  • Pérez-García, Víctor M.|||0000-0002-6575-495X
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
Chromosomal instability (CIN) lies at the core of cancer development leading to aneuploidy, chromosomal copy-number heterogeneity (chr-CNH) and ultimately, unfavorable clinical outcomes. Despite its ubiquity in cancer, the presence of CIN in childhood B-cell acute lymphoblastic leukemia (cB-ALL), the most frequent pediatric cancer showing high frequencies of aneuploidy, remains unknown. Here, we elucidate the presence of CIN in aneuploid cB-ALL subtypes using single-cell whole-genome sequencing of primary cB-ALL samples and by generating and functionally characterizing patient-derived xenograft models (cB-ALL-PDX). We report higher rates of CIN across aneuploid than in euploid cB-ALL that strongly correlate with intraclonal chr-CNH and overall survival in mice. This association was further supported by in silico mathematical modeling. Moreover, mass-spectrometry analyses of cB-ALL-PDX revealed a "CIN signature" enriched in mitotic-spindle regulatory pathways, which was confirmed by RNA-sequencing of a large cohort of cB-ALL samples. The link between the presence of CIN in aneuploid cB-ALL and disease progression opens new possibilities for patient stratification and offers a promising new avenue as a therapeutic target in cB-ALL treatment.